Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)
 
 • Company Description   
Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

Number of Employees: 31

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.08 Daily Weekly Monthly
20 Day Moving Average: 255,324 shares
Shares Outstanding: 49.58 (millions)
Market Capitalization: $400.57 (millions)
Beta: -1.00
52 Week High: $24.30
52 Week Low: $5.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 32.24% 42.03%
12 Week -12.27% 2.93%
Year To Date -47.12% -34.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3415 COLORADO AVE.
-
BOULDER,CO 80303
USA
ph: 720-262-7002
fax: -
ir@edgewisetx.com http://www.edgewisetx.com
 
 • General Corporate Information   
Officers
Kevin Koch - President; Chief Executive Officer and Director
Peter Thompson - Chairman and Director
R. Michael Carruthers - Chief Financial Officer
Alan Russell - Chief Scientific Officer and Director
Laura A. Brege - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28036F105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 49.58
Most Recent Split Date: (:1)
Beta: -1.00
Market Capitalization: $400.57 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.54
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -114.29%
vs. Previous Quarter: -15.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/22 - -
03/31/22 - -18.14
12/31/21 - -12.46
ROA
06/30/22 - -
03/31/22 - -17.53
12/31/21 - -12.13
Current Ratio
06/30/22 - -
03/31/22 - 26.85
12/31/21 - 26.97
Quick Ratio
06/30/22 - -
03/31/22 - 26.85
12/31/21 - 26.97
Operating Margin
06/30/22 - -
03/31/22 - -
12/31/21 - -
Net Margin
06/30/22 - -
03/31/22 - -
12/31/21 - -
Pre-Tax Margin
06/30/22 - -
03/31/22 - -
12/31/21 - -
Book Value
06/30/22 - -
03/31/22 - 5.25
12/31/21 - 5.57
Inventory Turnover
06/30/22 - -
03/31/22 - -
12/31/21 - -
Debt-to-Equity
06/30/22 - -
03/31/22 - 0.00
12/31/21 - 0.00
Debt-to-Capital
06/30/22 - -
03/31/22 - 0.00
12/31/21 - 0.00
 

Powered by Zacks Investment Research ©